Navigation Links
United States Patent and Trademark Office Publishes Stemedica's Patent Application for the Treatment of Diabetic Retinopathy
Date:9/8/2009

SAN DIEGO, Sept. 8 /PRNewswire/ -- http://www.stemedica.com/ Stemedica Cell Technologies, Inc., ("Stemedica"), a world leader in stem cell research and manufacturing, has filed a patent application with the United States Patent and Trademark Office ("USPTO") for a proprietary methodology in the treatment for Diabetic Retinopathy. The patent application was published by the USPTO on August 27th of this year. The application is supported by extensive data and results from patients treated within a Clinical Study conducted outside of the United States beginning in January of 2006.

"Our patent application describes a dynamic method for treating diabetic retinopathy and other degenerative conditions of the eye," said Nikolai Tankovich, MD, PhD, Stemedica's President and Chief Medical Officer. "The breakthrough results from this study provide new hope for the thousands of patients suffering from the debilitating disease of Diabetic Retinopathy."

Stemedica's invention relates to the use of multiple stem cells and a transplantation methodology in the treatment of Diabetic Retinopathy. Participating patients had varying degrees of Diabetic Retinopathy and Diabetic Optic Neuropathy. Patients received neural progenitor cells by retrobulbar injection and mesenchymal stem cells administered intravenously. Patients were observed at baseline and then after treatment at days 2, 8, 14, 30, 60, 90, and 120. Annual physical and ophthalmic examinations were conducted each year thereafter for a three year period.

Noticeable patient findings included: overall visual function improvements by all eight patients within sixty (60) days of treatment; reduction in absolute scotomas; increases in the thickness of the optic nerve fiber; resorption of hemorrhages; no new micro bleeding edema of the nerve fiber layer; and, a decrease in macular edema. Improvement in the function of different layers of the retina and optic nerve were experienced as well as a reduction in the number of scotomas in the field of vision. None of the patients developed tumors, had impaired vision or experienced adverse health effects connected with the cell injections, and seven of the eight participating patients have maintained the overall vision improvements they gained from treatment three years later.

Diabetic retinopathy is damage to the eye's retina that occurs with long-term diabetes. It is a leading cause of adult blindness in the United States.

This patent application, Publication Number US2009/0214485 A1, is available for review via the USPTO at www.uspto.gov.

About Stemedica Cell Technologies, Inc. Stemedica Cell Technologies Inc. (www.stemedica.com) is a specialty biopharmaceutical company that is committed to the development and manufacturing of best-in-class adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and human clinical trials. The company is currently developing regulatory pathways for stroke and wound repair. Stemedica is headquartered in San Diego, California.

For more information regarding Stemedica Cell Technologies, Inc. contact Dave McGuigan at dmcguigan@stemedica.com.


'/>"/>
SOURCE Stemedica Cell Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
2. Premier Research Expands its Medical Device Operations to the United States
3. American Oriental Bioengineering to Initiate a Phase One Clinical Trial in the United States of AOBO-001 Oral Capsule
4. A First-Line Therapy for Renal Cell Carcinoma that can Increase Overall Survival when Compared with Sutent Would Earn a Higher Patient Share in the United States Than in Europe
5. Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. United States, Canada and Mexico Agree to Mutual Assistance During Public Health Emergencies
8. R-CALF United Stockgrowers of America: Fighting for the U.S. Cattle Producer
9. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
10. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
11. Vaccine Study in New England Journal of Medicine Wrong in Concluding Mercury Exposures are Harmless, States SafeMinds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... 2016 Tie-up with Government hospitals ... to save newborns   Fortis La Femme, ... in collaboration with Breast Milk Foundation (BMF), a non-profit organization ... Milk Bank, ,Amaara, in Delhi-NCR today. This non-profit centre recognizes ... infants and should be available to babies deprived of mother,s ...
(Date:4/27/2016)... 2016 Oasmia Pharmaceutical AB ... a new generation of drugs within human and ... for Paclical/Apealea in the Phase III study that ... ovarian cancer. These preliminary results showed non-inferiority between ... carboplatin versus Taxol in combination with carboplatin. In ...
(Date:4/26/2016)... FLINT, Mich. , April 26, 2016 ... the promotion of Jennifer Hagerman , Pharm D., ... In her growing role at Diplomat, Hagerman will continue ... of the company that delivers custom education and training ... to the specialty pharmacy industry. Diplomat University also houses ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... April 30, 2016 , ... Orlando-based Maximized Living has selected Dr. ... gold in Rio. Under the care of Maximized Living doctors at the London ... unprecedented showing, Maximized Living is sending the largest contingent of elite chiropractors to Rio ...
(Date:4/29/2016)... ... April 29, 2016 , ... Memorial Healthcare System Graduate ... Education (ACGME) that it has received accreditation for its residency program on Physical ... programs that Memorial is currently pursuing, including Pediatrics and Internal Medicine. This accreditation ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... and author of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related ... 2016 and podcasted thereafter . Dr. Bernie Siegel, author of a plethora ...
(Date:4/29/2016)... ... April 29, 2016 , ... Spine Team Texas, a comprehensive spine physician ... one of their physicians has been invited to be a featured speaker at the ... Review conference on April 30, 2016. , Dr. R. Scott McPherson, a physical ...
(Date:4/29/2016)... ... 29, 2016 , ... Melanoma is the deadliest type of skin cancer. Although only about 1 ... skin cancer deaths. More than 10,000 people are expected to die of melanoma this year. ... is the one of the most commonly diagnosed cancers in young women. A recent breakthrough ...
Breaking Medicine News(10 mins):